Insider Transactions Reported by 19 Insiders of NextCure, Inc.

Symbol: NXTC on Nasdaq
Location: Beltsville, MD

Key facts

NXTC - NextCure, Inc. has 19 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are available for direct filing-level review.

Change

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 23 May 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

NextCure, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Simcere Zaiming, Inc.	10%+ Owner	$152,386	Market	20 Jun 2025
Kevin G. Shaw	Sr VP, General Counsel		Mixed	30 Jan 2026
Han Myint	Chief Medical Officer		Mixed	29 Mar 2024
Udayan Guha	Chief Medical Officer		Mixed	30 Jan 2026
KABAKOFF DAVID S	Director		Mixed	20 Jun 2025
Ellen Feigal	Director		Mixed	20 Jun 2025
Michael Richman	President & CEO, Director		Mixed	30 Jan 2026
Stella Xu	Director		Mixed	24 Jun 2021
Chau Q. Khuong	Director		Mixed	22 Jun 2023
Stephen W. Webster	Director		Mixed	20 Jun 2025
Linda Liu	SVP, Research		Mixed	31 Jan 2022
Sourav Kundu	Sr VP, Dev. & Mfg.		Mixed	30 Jan 2026
Anne Elizabeth Borgman	Director		Mixed	20 Jun 2025
Elaine V Jones	Director		Mixed	20 Jun 2025
Sol Langermann	Chief Scientific Officer		Mixed	31 Jan 2025
Steven P. Cobourn	Chief Financial Officer		Mixed	30 Jan 2026
Timothy Mayer	Chief Operating Officer		Mixed	30 Jan 2026
Garry A. Nicholson	Director		Mixed	22 Jun 2023
John G. Houston	Director		Mixed	20 Jun 2025

Top shareholders of NextCure, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Ikarian Capital, LLC	13D/G 13F	Company	10%	363,035	$4,715,825	$0	31 Dec 2025	13D/G 13F
Affinity Asset Advisors, LLC	13D/G 13F	Company	10%	348,607	$4,375,018	+$1,966,899	22 Jan 2026	13D/G 13F
Squadron Capital Management LLC	13D/G 13F	Squadron Master Fund LP · Company	9.9%	271,127	$3,521,940	+$1,263,485	31 Dec 2025	13D/G 13F
Simcere Zaiming, Inc.	13D/G 3/4/5	10%+ Owner	9.4%	338,636	$152,386	$0	31 Dec 2025	13D/G 3/4/5
Sofinnova Venture Partners IX, L.P.	13D/G	Sofinnova Venture Partners IX, L.P. ("SVP IX")	7.1%	222,654	$2,947,939	$0	19 Dec 2025	13D/G
SILVERARC CAPITAL MANAGEMENT, LLC	13D/G 13F	Company	5%	176,057	$2,286,980	$0	31 Dec 2025	13D/G 13F
CITIGROUP INC	13D/G 13F	Citigroup Global Markets Inc. · Company	4.3%	1,205,193	$506,181	$0	31 Mar 2025	13D/G 13F
PFIZER INC	13F 13D/G	Company · Pfizer Inc. (IRS Identification No.: 13-5315170)	3% from 13D/G	153,354	$1,535,074	—	31 Mar 2026	13F 13D/G
Sofinnova Investments, Inc.	13F	Company	7.1%	222,654	$2,377,945	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	5.1%	160,473	$1,688,176	—	31 Mar 2026	13F
Opaleye Management Inc.	13F	Company	4.5%	141,181	$1,507,813	—	31 Mar 2026	13F
AWM Investment Company, Inc.	13F	Company	3.7%	117,371	$1,234,743	—	31 Mar 2026	13F
Exome Asset Management LLC	13F	Company	3.7%	115,500	$1,215,060	—	31 Mar 2026	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	2.2%	69,617	$743,510	—	31 Mar 2026	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.9%	60,534	$646,503	—	31 Mar 2026	13F
Verdad Advisers, LP	13F	Company	1.4%	42,955	$458,759	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.99%	31,092	$327,136	—	31 Mar 2026	13F
BlackRock, Inc.	13F	Company	0.89%	27,793	$296,830	—	31 Mar 2026	13F
Woodline Partners LP	13F	Company	0.88%	27,498	$293,679	—	31 Mar 2026	13F
CARDIFF PARK ADVISORS, LLC	13F	Company	0.7%	21,833	$233,176	—	31 Mar 2026	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.61%	18,982	$199,000	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.51%	16,015	$168,478	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	0.49%	15,292	$160,872	—	31 Mar 2026	13F
BARCLAYS PLC	13F	Company	0.18%	5,626	$60,085	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.01%	338	$3,610	—	31 Mar 2026	13F
MORGAN STANLEY	13F	Company	0%	66	$705	—	31 Mar 2026	13F
JPMORGAN CHASE & CO	13F	Company	0%	61	$587	—	31 Mar 2026	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	32	$342	—	31 Mar 2026	13F
Sol Langermann	3/4/5	Chief Scientific Officer	— class O/S missing	211,275	—	—	31 Jan 2025	3/4/5
Han Myint	3/4/5	Chief Medical Officer	— class O/S missing	93,900	—	—	29 Mar 2024	3/4/5
Linda Liu	3/4/5	SVP, Research	— class O/S missing	65,600	—	—	31 Jan 2022	3/4/5
Michael Richman	3/4/5	President & CEO, Director	— class O/S missing	38,190	—	—	30 Jan 2026	3/4/5
KABAKOFF DAVID S	3/4/5	Director	— class O/S missing	28,050	—	—	20 Jun 2025	3/4/5
Anne Elizabeth Borgman	3/4/5	Director	— class O/S missing	18,700	—	—	20 Jun 2025	3/4/5
Elaine V Jones	3/4/5	Director	— class O/S missing	18,700	—	—	20 Jun 2025	3/4/5
Ellen Feigal	3/4/5	Director	— class O/S missing	18,700	—	—	20 Jun 2025	3/4/5
John G. Houston	3/4/5	Director	— class O/S missing	18,700	—	—	20 Jun 2025	3/4/5
Stephen W. Webster	3/4/5	Director	— class O/S missing	18,700	—	—	20 Jun 2025	3/4/5
Steven P. Cobourn	3/4/5	Chief Financial Officer	— class O/S missing	14,670	—	—	30 Jan 2026	3/4/5
Timothy Mayer	3/4/5	Chief Operating Officer	— class O/S missing	14,670	—	—	30 Jan 2026	3/4/5
Udayan Guha	3/4/5	Chief Medical Officer	— class O/S missing	14,670	—	—	30 Jan 2026	3/4/5
Chau Q. Khuong	3/4/5	Director	— class O/S missing	14,250	—	—	22 Jun 2023	3/4/5
Garry A. Nicholson	3/4/5	Director	— class O/S missing	14,250	—	—	22 Jun 2023	3/4/5
Stella Xu	3/4/5	Director	— class O/S missing	14,250	—	—	24 Jun 2021	3/4/5
Kevin G. Shaw	3/4/5	Sr VP, General Counsel	— class O/S missing	8,270	—	—	30 Jan 2026	3/4/5
Sourav Kundu	3/4/5	Sr VP, Dev. & Mfg.	— class O/S missing	8,270	—	—	30 Jan 2026	3/4/5

Recent Insider Transactions by Companies or Individuals for NextCure, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	Shares	Shares Owned	Date	Ownership
Kevin G. Shaw	NXTC	Employee Stock Option (Right to Buy)	Award	8,270	8,270	30 Jan 2026	Direct
Sourav Kundu	NXTC	Employee Stock Option (Right to Buy)	Award	8,270	8,270	30 Jan 2026	Direct
Timothy Mayer	NXTC	Employee Stock Option (Right to Buy)	Award	14,670	14,670	30 Jan 2026	Direct
Udayan Guha	NXTC	Employee Stock Option (Right to Buy)	Award	14,670	14,670	30 Jan 2026	Direct
Steven P. Cobourn	NXTC	Employee Stock Option (Right to Buy)	Award	14,670	14,670	30 Jan 2026	Direct
Michael Richman	NXTC	Employee Stock Option (Right to Buy)	Award	38,190	38,190	30 Jan 2026	Direct
John G. Houston	NXTC	Stock Option (Right to Buy)	Award	18,700	18,700	20 Jun 2025	Direct
Elaine V Jones	NXTC	Stock Option (Right to Buy)	Award	18,700	18,700	20 Jun 2025	Direct
Kabakoff David S	NXTC	Stock Option (Right to Buy)	Award	28,050	28,050	20 Jun 2025	Direct
Anne Elizabeth Borgman	NXTC	Stock Option (Right to Buy)	Award	18,700	18,700	20 Jun 2025	Direct
Stephen W. Webster	NXTC	Stock Option (Right to Buy)	Award	18,700	18,700	20 Jun 2025	Direct
Ellen Feigal	NXTC	Stock Option (Right to Buy)	Award	18,700	18,700	20 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.